로딩 중…
지수 로딩 중…
Trevi Therapeutics, Inc.
TRVI· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$17.90-1.92%
2026-08-03
Financials
Valuation Metrics
Trevi Therapeutics, Inc.'s Market Cap is $2.54B. At end of 2025 it was $1.82B. Ranked #1898 of 3,112 in US market (top 61%), #699 of 1,445 on NASDAQ (top 48%), #113 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 42%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.54B | US#1,898/3,112 Sec#113/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-46M | US—/3,112 Sec—/269 |
| Total Assets | $180M | US#2,994/3,112 Sec#253/269 |
| Net Assets | $172M | US#2,779/3,112 Sec#207/269 |
| Value | ||
| P/B | 14.76x | US#2,730/3,112 Sec#218/269 |
| FCF Yield | -1.26% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -26.50% | US#2,581/3,112 Sec#116/269 |
| ROA | -25.39% | US#2,830/3,112 Sec#145/269 |
| Financial Health | ||
| Debt Ratio | 4.34% | US#39/3,112 Sec#14/269 |
| Total Debt | $682000.00 | US#2,941/3,112 Sec#250/269 |
| FCF | $-32M | US#2,417/3,112 Sec#104/269 |
| Cash | $19M | US#2,869/3,112 Sec#261/269 |
| Current Ratio | 24.75x | US#102/3,112 Sec#18/269 |
| Performance | ||
| 1Y Return | 144.20% | US#176/3,112 Sec#55/269 |
| 1M Return | -0.17% | US#1,677/3,112 Sec#78/269 |
| From 52W High | -11.47% | US#1,149/3,112 Sec#64/269 |
| 1Y MDD | -29.50% | US#1,343/3,112 Sec#85/269 |
| Trading | ||
| Volume | 1,237,367 shares | US#1,305/3,112 Sec#130/269 |
| Trading Value | $22M | US#1,901/3,112 Sec#138/269 |
| Per Share | ||
| EPS | $-0.29 | US—/3,112 Sec—/269 |
| BPS | $1.26 | US#2,590/3,112 Sec#195/269 |